SNPMiner Trials (Home Page)
Report for SNP rs6165
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 Assessing the Relation Between Hormone Receptors Gene Polymorphism and Ovarian Stimulation Response in In Vitro Fertilization (IVF) Program
The aim of this study is to assess the role of AMH in prediction of poor ovarian response as well as the relation between ESR2 (+1730G>A) (rs4986938), FSHR p.Thr307Ala (c.919A>G, rs6165) and FSHR p.Asn680Ser (c.2039A>G, rs6166) SNPs and the poor response in Egyptian women undergoing IVF procedure. Discovering the genetic variants associated with ovarian response is an important step towards individualized pharmacogenetic protocols of ovarian stimulation.
NCT02640976 Infertility Drug: Human menopausal gonadotrophin (HMG) Drug: GnRH antagonist Cetrorelix Drug: Human chorionic gonadotrophin (hCG) MeSH:Infertility
HPO:Infertility
Poor Ovarian Stimulation Response in In Vitro Fertilization (IVF) Program The aim of this study is to assess the role of AMH in prediction of poor ovarian response as well as the relation between ESR2 (+1730G>A) (rs4986938), FSHR p.Thr307Ala (c.919A>G, rs6165) and FSHR p.Asn680Ser (c.2039A>G, rs6166) SNPs and the poor response in Egyptian women undergoing IVF procedure.
36 hours later, oocyte retrieval will be performed and will be guided by transvaginal ultrasound.. Detection of the single nucleotide polymorphisms ESR2(+1730G>A) (rs4986938), FSHR p.Thr307Ala (c.919A>G, rs6165) and FSHR p.Asn680Ser (c.2039A>G, rs6166) SNPs will be performed using the TaqMan system by real-time polymerase chain reaction (PCR).
Detection of the polymorphisms ESR2 (+1730G>A) (rs4986938), FSHR p.Thr307Ala (c.919A>G, rs6165) and FSHR p.Asn680Ser (c.2039A>G, rs6166) SNPs will be performed using the TaqMan system by real-time polymerase chain reaction (PCR).
Primary Outcomes
Description: when at least 3 follicles will reach 17 mm in diameter, ovulation will be triggered by a single intra-muscular injection of 10,000 IU of hCG [Choriomon® 5000 IU ampoules, IBSA institut]. 36 hours later, oocyte retrieval will be performed and will be guided by transvaginal ultrasound.
Measure: number of oocytes collected Time: 3 weeks from of start of ICSI cycleSecondary Outcomes
Description: By using PCR, we will indicate the genotype in each individual and determine the probability of the poor ovarian response.
Measure: Detection of the single nucleotide polymorphisms ESR2(+1730G>A) (rs4986938), FSHR p.Thr307Ala (c.919A>G, rs6165) and FSHR p.Asn680Ser (c.2039A>G, rs6166) SNPs will be performed using the TaqMan system by real-time polymerase chain reaction (PCR) Time: Within 1 weekOther Outcomes
Description: Based on FSH level, the dose of HMG ( Merional) will be adjusted for each individual.
Measure: Laboratory analysis of basal follicle stimulating hormone level for each individual will be measured by enzyme-linked immunosorbent assay (ELISA) Time: Done within 3 months preceeding the ICSI cycleDescription: Based on AMH level, the dose of HMG (Merional) will be adjusted for each individual.
Measure: Laboratory analysis of anti-mullerian hormone level (AMH) will be measured by ELISA technique for each individual. Time: Done within 3 months preceeding the ICSI cycle.